EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ability of the MeltPro MTB/PZA Assay to Detect Susceptibility to Pyrazinamide in Rifampin-Resistant Tuberculosis Patients

Rong Li, Yang Li, Xinchang Chen, Lina Jia, Hongying Yu, Ya Huang, Qianhong Wu, Mingying Xiao, Shijia Ge, Yilin Zhang, Zhen Feng, Qingge Li iD und 4 weitere

Microbiology Spectrum · 2023

DOI: 10.1128/spectrum.04836-22 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2023. Verfasst von Rong Li und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Jing'an District Central Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Tuberculosis, Mycobacterium tuberculosis, Tuberculosis, Multidrug-Resistant. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Clinical Research Plan of SHDC, National Natural Science Foundation of China, Shanghai Sailing Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study evaluated the accuracy of the MeltPro MTB/PZA assay at detecting the presence of PZA resistance through registered clinical trials. Compared to DNA sequencing, the assay had high sensitivity and negative predictive value, suggesting its potential utility as a screening tool in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TuberculosisMycobacterium tuberculosisTuberculosis, Multidrug-ResistantHumansPyrazinamideRifampinAntitubercular AgentsMicrobial Sensitivity TestsMutationDrug Resistance, Bacterial

Stichwörter der Autor:innen

MeltPro MTB/PZA assaydrug susceptibility testingmelting curve analysispyrazinamide

Substanzen

PyrazinamideRifampinAntitubercular Agents

Autor:innen und Institutionen

  • Department of Infectious Diseases, Jing'an District Central Hospital, Fudan University, Shanghai, China.
  • Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.
  • Department of Tuberculosis, Guiyang Public Health Clinical Center, Guiyang, China.
  • Center for Infectious Diseases, The First People's Hospital of Huaihua, Huaihua, Hunan, China.
  • Department of Tuberculosis, Ge Jiu Infectious Disease Hospital, Gejiu, China.
  • Department of Tuberculosis, Shaanxi Provincial Tuberculosis Prevention and Control Hospital, Xi'an, Shannxi, China.

ORCID-Profile: Qingge Li, Feng Sun

Förderung

  • Clinical Research Plan of SHDC
  • National Natural Science Foundation of China
  • Shanghai Sailing Program
  • Shanghai Municipal Science, Technology Major Project
  • Wenhong Zhang Station in Yunnan Province
  • Shanghai Science and Technology Committee

Zitieren

APA

Li, R., Li, Y., Chen, X., Jia, L., Yu, H., Huang, Y., Wu, Q., Xiao, M., Ge, S., Zhang, Y., Feng, Z., Li, Q., Xu, Y., Shi, W., Sun, F., & Zhang, W. (2023). Ability of the MeltPro MTB/PZA Assay to Detect Susceptibility to Pyrazinamide in Rifampin-Resistant Tuberculosis Patients. Microbiology Spectrum. https://doi.org/10.1128/spectrum.04836-22

Vancouver

Li R, Li Y, Chen X, Jia L, Yu H, Huang Y, et al. Ability of the MeltPro MTB/PZA Assay to Detect Susceptibility to Pyrazinamide in Rifampin-Resistant Tuberculosis Patients. Microbiology Spectrum. 2023. doi:10.1128/spectrum.04836-22

BibTeX
@article{Li2023,
  author = {Li, Rong and Li, Yang and Chen, Xinchang and Jia, Lina and Yu, Hongying and Huang, Ya and Wu, Qianhong and Xiao, Mingying and Ge, Shijia and Zhang, Yilin and Feng, Zhen and Li, Qingge and Xu, Ye and Shi, Wenzhi and Sun, Feng and Zhang, Wenhong},
  title = {Ability of the MeltPro MTB/PZA Assay to Detect Susceptibility to Pyrazinamide in Rifampin-Resistant Tuberculosis Patients},
  journal = {Microbiology Spectrum},
  year = {2023},
  doi = {10.1128/spectrum.04836-22}
}
Kostenlos starten →